Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: Iowa 25 trials found
New Search
Filter
Trial Phase
Study Type
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Quantitative MRI Assessment of Breast Cancer Therapy Response
N/AOBSERVATIONAL Iowa City, Iowa +3 more
RECRUITING
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Preop Laxatives in Robotic Urologic Surgery
PHASE4INTERVENTIONAL Iowa City, Iowa
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
N/AOBSERVATIONAL Santa Monica, California +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
PHASE2INTERVENTIONAL Indianapolis, Indiana +3 more
RECRUITING
Lurbinectedin in FET-Fused Tumors
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
PHASE1INTERVENTIONAL Augusta, Georgia +4 more
RECRUITING
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
PHASE1INTERVENTIONAL Beverly Hills, California +4 more
RECRUITING
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
PHASE2, PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
PHASE1INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Test-retest Evaluation of [18F]F-AraG PET
PHASE2INTERVENTIONAL Iowa City, Iowa
RECRUITING
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
PHASE1INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
PHASE2INTERVENTIONAL Iowa City, Iowa
RECRUITING
GEMINI-NSCLC: NSCLC Biomarker Study
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
PHASE3INTERVENTIONAL Orange, California +4 more
RECRUITING
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
PHASE4INTERVENTIONAL Chicago, Illinois +2 more
RECRUITING
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
N/AOBSERVATIONAL Los Angeles, California +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type